Apimeds Pharmaceuticals US Inc
APUS
View Detailed Chart
2.020USD
+0.150+8.20%
Close 09/19, 16:00（ET）Quotes delayed by 15 min
25.40MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+8.20%
5 Days
-2.88%
1 Month
+6.32%
6 Months
0.00%
Year to Date
0.00%
1 Year
0.00%
View Detailed Chart
TradingKey Stock Score
No scoring data
News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
Company
Apimeds Pharmaceuticals US, Inc., is a clinical-stage biopharmaceutical company. The Company is engaged in developing Apitox, an intradermally administered bee venom-based toxin. It is focused on developing Apitox as a potential osteoarthritis (OA) treatment for patients with knee pain who failed to respond adequately to conservative non- pharmacologic therapy and simple analgesics.
Ticker SymbolAPUS
CompanyApimeds Pharmaceuticals US Inc
CEOMr. Erik C. Emerson
Websitehttps://www.apimedsus.com/
Related Instruments
+0.68%
+0.77%
-2.48%
-1.58%
-0.75%
-0.09%
+1.34%
-1.77%
-0.67%
-3.03%
-0.85%
-0.87%
-0.50%
+0.42%
-0.19%
-1.18%
-1.83%
0.00%
+0.30%
-3.72%
